{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import numpy as np"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "df = pd.read_csv(\"expandedacess _available_and_marketing.csv\" , sep=\",\", error_bad_lines=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Rank</th>\n",
       "      <th>NCT Number</th>\n",
       "      <th>Title</th>\n",
       "      <th>Acronym</th>\n",
       "      <th>Status</th>\n",
       "      <th>Study Results</th>\n",
       "      <th>Conditions</th>\n",
       "      <th>Interventions</th>\n",
       "      <th>Outcome Measures</th>\n",
       "      <th>Sponsor/Collaborators</th>\n",
       "      <th>...</th>\n",
       "      <th>Other IDs</th>\n",
       "      <th>Start Date</th>\n",
       "      <th>Primary Completion Date</th>\n",
       "      <th>Completion Date</th>\n",
       "      <th>First Posted</th>\n",
       "      <th>Results First Posted</th>\n",
       "      <th>Last Update Posted</th>\n",
       "      <th>Locations</th>\n",
       "      <th>Study Documents</th>\n",
       "      <th>URL</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>NCT03564964</td>\n",
       "      <td>Expanded Access to Provide SUVN-502 for the Tr...</td>\n",
       "      <td>SUVN-502</td>\n",
       "      <td>Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Alzheimer Disease|Dementia|Cognition Disorders</td>\n",
       "      <td>Drug: SUVN-502</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Suven Life Sciences Limited</td>\n",
       "      <td>...</td>\n",
       "      <td>EAP1502HT6</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>21-Jun-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>25-Jun-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT03564964</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2</td>\n",
       "      <td>NCT03561194</td>\n",
       "      <td>Omegaven Protocol:Intermediate Size Patient Po...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Parenteral Nutrition Associated Liver Disease</td>\n",
       "      <td>Other: Omegaven</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Doctors Hospital at Renaissance</td>\n",
       "      <td>...</td>\n",
       "      <td>2</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>19-Jun-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>19-Jun-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT03561194</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>3</td>\n",
       "      <td>NCT03559686</td>\n",
       "      <td>Named Patient Program With Certolizumab Pegol ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Rheumatoid Arthritis</td>\n",
       "      <td>Drug: Certolizumab Pegol</td>\n",
       "      <td>NaN</td>\n",
       "      <td>UCB Biopharma S.P.R.L.|UCB Pharma</td>\n",
       "      <td>...</td>\n",
       "      <td>RA0039</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>18-Jun-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>18-Jun-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT03559686</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>4</td>\n",
       "      <td>NCT03559673</td>\n",
       "      <td>Compassionate Use Program With Lacosamide in P...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Epilepsies, Partial</td>\n",
       "      <td>Drug: Lacosamide</td>\n",
       "      <td>NaN</td>\n",
       "      <td>UCB Biopharma S.P.R.L.|UCB Pharma</td>\n",
       "      <td>...</td>\n",
       "      <td>EP0072</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>18-Jun-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>18-Jun-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT03559673</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>5</td>\n",
       "      <td>NCT03559660</td>\n",
       "      <td>CUP Certolizumab Pegol (CDP-870) in Adults Suf...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Crohn's Disease</td>\n",
       "      <td>Drug: Certolizumab Pegol</td>\n",
       "      <td>NaN</td>\n",
       "      <td>UCB Biopharma S.P.R.L.|UCB Pharma</td>\n",
       "      <td>...</td>\n",
       "      <td>C87092</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>18-Jun-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>18-Jun-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT03559660</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>6</td>\n",
       "      <td>NCT03544060</td>\n",
       "      <td>Volanesorsen Early Access Program for Patients...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Familial Chylomicronemia</td>\n",
       "      <td>Drug: Volanesorsen</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Akcea Therapeutics|CaligorRx, Inc.</td>\n",
       "      <td>...</td>\n",
       "      <td>ISIS 304801</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1-Jun-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1-Jun-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT03544060</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>7</td>\n",
       "      <td>NCT03539393</td>\n",
       "      <td>Expanded Access Program for Patients With Migr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Migraine|Cluster Headache</td>\n",
       "      <td>Drug: Fremanezumab</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Teva Branded Pharmaceutical Products, R&amp;D Inc....</td>\n",
       "      <td>...</td>\n",
       "      <td>TV48125-CNS-80005</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>28-May-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>28-May-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT03539393</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>8</td>\n",
       "      <td>NCT03539380</td>\n",
       "      <td>TRx0237 for the Treatment of Mild-Moderate Alz...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Alzheimer Disease</td>\n",
       "      <td>Drug: TRx0237</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TauRx Therapeutics Ltd</td>\n",
       "      <td>...</td>\n",
       "      <td>TRx-237-040</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>28-May-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>28-May-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT03539380</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>9</td>\n",
       "      <td>NCT03537807</td>\n",
       "      <td>Expanded Access Protocol of BHV-0223 for Patie...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Amyotrophic Lateral Sclerosis|ALS|Lou Gehrig D...</td>\n",
       "      <td>Drug: Riluzole</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Biohaven Pharmaceuticals, Inc.</td>\n",
       "      <td>...</td>\n",
       "      <td>BHV0223-401</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>25-May-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>7-Jun-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT03537807</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>10</td>\n",
       "      <td>NCT03533361</td>\n",
       "      <td>Expanded Access Program With Lenvatinib for th...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Approved for marketing</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Thyroid Cancer</td>\n",
       "      <td>Drug: Lenvatinib</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Eisai Inc.</td>\n",
       "      <td>...</td>\n",
       "      <td>E7080-M001-603</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>23-May-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>23-May-18</td>\n",
       "      <td>Hospital Sirio Libanes, Sao Paulo, São Paulo, ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT03533361</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>11</td>\n",
       "      <td>NCT03532516</td>\n",
       "      <td>Compassionate Use Program With Brivaracetam fo...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Epilepsy</td>\n",
       "      <td>Drug: Brivaracetam</td>\n",
       "      <td>NaN</td>\n",
       "      <td>UCB Biopharma S.P.R.L.|UCB Pharma</td>\n",
       "      <td>...</td>\n",
       "      <td>N01317</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>22-May-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>22-May-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT03532516</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>12</td>\n",
       "      <td>NCT03503890</td>\n",
       "      <td>Expanded Access to Rovalpituzumab Tesirine</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Small Cell Lung Cancer</td>\n",
       "      <td>Drug: rovalpituzumab tesirine</td>\n",
       "      <td>NaN</td>\n",
       "      <td>AbbVie</td>\n",
       "      <td>...</td>\n",
       "      <td>C18-915</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>20-Apr-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12-Jun-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT03503890</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>13</td>\n",
       "      <td>NCT03501940</td>\n",
       "      <td>F18 DCFPyL PET/CT in Imaging Participants With...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Prostate Adenocarcinoma|PSA Level Greater Than...</td>\n",
       "      <td>Procedure: Computed Tomography|Radiation: Fluo...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Andrei Iagaru|Stanford University</td>\n",
       "      <td>...</td>\n",
       "      <td>PROS0083|NCI-2018-00479|IRB-42701</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>18-Apr-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>4-Jun-18</td>\n",
       "      <td>Stanford Cancer Institute Palo Alto, Palo Alto...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT03501940</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>14</td>\n",
       "      <td>NCT03501615</td>\n",
       "      <td>An Early Access Programme for Moxetumomab Pasu...</td>\n",
       "      <td>MOXE</td>\n",
       "      <td>Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Relapsed/Refractory Hairy Cell Leukemia</td>\n",
       "      <td>Drug: Moxetumomab Pasudotox</td>\n",
       "      <td>NaN</td>\n",
       "      <td>AstraZeneca</td>\n",
       "      <td>...</td>\n",
       "      <td>D3143R00002</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>18-Apr-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>18-Apr-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT03501615</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>15</td>\n",
       "      <td>NCT03493165</td>\n",
       "      <td>Expanded Access to Everolimus, for an Individu...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Drug: Everolimus</td>\n",
       "      <td>NaN</td>\n",
       "      <td>The University of Texas Health Science Center ...</td>\n",
       "      <td>...</td>\n",
       "      <td>CTMS# 18-0020</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>10-Apr-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>10-Apr-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT03493165</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>16</td>\n",
       "      <td>NCT03493152</td>\n",
       "      <td>Expanded Access to Everolimus, for an Individu...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Gastrointestinal Stromal Tumor</td>\n",
       "      <td>Drug: Everolimus</td>\n",
       "      <td>NaN</td>\n",
       "      <td>The University of Texas Health Science Center ...</td>\n",
       "      <td>...</td>\n",
       "      <td>CTMS# 18-0019</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>10-Apr-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>10-Apr-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT03493152</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>17</td>\n",
       "      <td>NCT03492489</td>\n",
       "      <td>Expanded Access Protocol for Cemiplimab in Met...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Cutaneous Squamous Cell Carcinoma</td>\n",
       "      <td>Drug: cemiplimab</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Regeneron Pharmaceuticals|Sanofi</td>\n",
       "      <td>...</td>\n",
       "      <td>R2810-ONC-17103</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>10-Apr-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>25-Apr-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT03492489</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>18</td>\n",
       "      <td>NCT03462810</td>\n",
       "      <td>GSK1265744 (Cabotegravir, CAB) for Named Patie...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Infection, Human Immunodeficiency Virus</td>\n",
       "      <td>Drug: cabotegravir, CAB</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ViiV Healthcare</td>\n",
       "      <td>...</td>\n",
       "      <td>205741</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>13-Mar-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>13-Mar-18</td>\n",
       "      <td>GSK Investigational Site, San Francisco, Calif...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT03462810</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>19</td>\n",
       "      <td>NCT03439475</td>\n",
       "      <td>AMG 714 Expanded Access Program</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Biological: AMG 714</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Amgen</td>\n",
       "      <td>...</td>\n",
       "      <td>AMG714 Expanded Access Program</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>20-Feb-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>22-Feb-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT03439475</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>20</td>\n",
       "      <td>NCT03433807</td>\n",
       "      <td>Expanded Access Program for Idebenone in Parti...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Duchenne Muscular Dystrophy</td>\n",
       "      <td>Drug: Idebenone</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Santhera Pharmaceuticals</td>\n",
       "      <td>...</td>\n",
       "      <td>SNT-EAP-002</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>15-Feb-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>15-Feb-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT03433807</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>21</td>\n",
       "      <td>NCT03433131</td>\n",
       "      <td>Expanded Access Program to Provide Treatment W...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Narcolepsy Without Cataplexy|Narcolepsy With C...</td>\n",
       "      <td>Drug: Pitolisant</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Harmony Biosciences, LLC</td>\n",
       "      <td>...</td>\n",
       "      <td>HBS-101-CL-001</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>14-Feb-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>9-May-18</td>\n",
       "      <td>Sleep Disorders Center of Alabama, Birmingham,...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT03433131</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>22</td>\n",
       "      <td>NCT03420430</td>\n",
       "      <td>Expanded Access to Provide GL-ONC1 for the Tre...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Advanced Stage Cancer (Solid Tumor Disease for...</td>\n",
       "      <td>Biological: GL-ONC1</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Genelux Corporation</td>\n",
       "      <td>...</td>\n",
       "      <td>GL-ONC1-021</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2-Feb-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2-Feb-18</td>\n",
       "      <td>Florida Hospital Cancer Institute, Orlando, Fl...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT03420430</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>23</td>\n",
       "      <td>NCT03419949</td>\n",
       "      <td>Comparison of Oral Lamotrigine and Oral Pregab...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Acute and Chronic Pain Following Modified Radi...</td>\n",
       "      <td>Drug: oral lamotrigine 100 mg|Drug: oral prega...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Assiut University</td>\n",
       "      <td>...</td>\n",
       "      <td>Comparison of oral lamotrigine</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2-Feb-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>6-Feb-18</td>\n",
       "      <td>Salma Komy, Assiut, Egypt</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT03419949</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>24</td>\n",
       "      <td>NCT03414489</td>\n",
       "      <td>Expanded Access for the Treatment of Advanced ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Cholangiocarcinoma|Cholangiocarcinoma Non-rese...</td>\n",
       "      <td>Drug: ABC294640</td>\n",
       "      <td>NaN</td>\n",
       "      <td>RedHill Biopharma Limited</td>\n",
       "      <td>...</td>\n",
       "      <td>ABC-108-EA</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>30-Jan-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>30-Jan-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT03414489</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>25</td>\n",
       "      <td>NCT03412539</td>\n",
       "      <td>Mechanism of Effectiveness of Neurosurgery Tre...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Oncology Problem</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tel-Aviv Sourasky Medical Center|University of...</td>\n",
       "      <td>...</td>\n",
       "      <td>TASMC-0354-17-TLV</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>26-Jan-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>26-Jan-18</td>\n",
       "      <td>Neurosurgery, Tel-Aviv Sourasky MC, Tel Aviv, ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT03412539</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>26</td>\n",
       "      <td>NCT03409081</td>\n",
       "      <td>Early Access Program (EAP) of Gilteritinib (AS...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Acute Myeloid Leukemia (AML)|FMS-like Tyrosine...</td>\n",
       "      <td>Drug: gilteritinib</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Astellas Pharma Global Development, Inc.|Astel...</td>\n",
       "      <td>...</td>\n",
       "      <td>2215-CL-9200</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>24-Jan-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>8-May-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT03409081</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>27</td>\n",
       "      <td>NCT03400098</td>\n",
       "      <td>ATTR Expanded Access Program (EAP) by Ionis</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Amyloidosis, Hereditary</td>\n",
       "      <td>Drug: Inotersen</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Ionis Pharmaceuticals, Inc.|Clinigen Group PLC</td>\n",
       "      <td>...</td>\n",
       "      <td>ISIS 420915-CS5</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>17-Jan-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12-Jun-18</td>\n",
       "      <td>Mayo Clinic Cancer Center, Scottsdale, Arizona...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT03400098</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>28</td>\n",
       "      <td>NCT03395769</td>\n",
       "      <td>Individual Patient Expanded Access for AB-SA01...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Biological: AB-SA01</td>\n",
       "      <td>NaN</td>\n",
       "      <td>AmpliPhi Biosciences Corporation</td>\n",
       "      <td>...</td>\n",
       "      <td>AB-SA01-EAP01</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>10-Jan-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>10-Jan-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT03395769</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>29</td>\n",
       "      <td>NCT03395743</td>\n",
       "      <td>Individual Patient Expanded Access for AB-PA01...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Biological: AB-PA01</td>\n",
       "      <td>NaN</td>\n",
       "      <td>AmpliPhi Biosciences Corporation</td>\n",
       "      <td>...</td>\n",
       "      <td>AB-PA01-EAP01</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>10-Jan-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>10-Jan-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT03395743</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>30</td>\n",
       "      <td>NCT03386071</td>\n",
       "      <td>Compassionate Use: Progressive Metastatic Cast...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Progressive Metastatic Castrate Resistant Pros...</td>\n",
       "      <td>Drug: Trametinib 2 mg</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Jonsson Comprehensive Cancer Center|Novartis</td>\n",
       "      <td>...</td>\n",
       "      <td>17-001886|Compassionate Use Trametinib</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>29-Dec-17</td>\n",
       "      <td>NaN</td>\n",
       "      <td>4-Jan-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT03386071</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>252</th>\n",
       "      <td>253</td>\n",
       "      <td>NCT00650026</td>\n",
       "      <td>Early Access Program of the Safety of Human An...</td>\n",
       "      <td>ReAct</td>\n",
       "      <td>Approved for marketing</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Rheumatoid Arthritis</td>\n",
       "      <td>Biological: adalimumab</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Abbott</td>\n",
       "      <td>...</td>\n",
       "      <td>M03-583</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1-Apr-08</td>\n",
       "      <td>NaN</td>\n",
       "      <td>14-Apr-08</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00650026</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>253</th>\n",
       "      <td>254</td>\n",
       "      <td>NCT00649545</td>\n",
       "      <td>Study of the Human Anti-TNF Monoclonal Antibod...</td>\n",
       "      <td>CanAct</td>\n",
       "      <td>Approved for marketing</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Rheumatoid Arthritis</td>\n",
       "      <td>Biological: adalimumab</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Abbott</td>\n",
       "      <td>...</td>\n",
       "      <td>M02-574</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1-Apr-08</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1-Apr-08</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00649545</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>254</th>\n",
       "      <td>255</td>\n",
       "      <td>NCT00642057</td>\n",
       "      <td>Compassionate Use of Tetrabenazine in the Trea...</td>\n",
       "      <td>TBZ</td>\n",
       "      <td>Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Hyperkinetic Movement Disorders</td>\n",
       "      <td>Drug: tetrabenazine</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Christine Hunter|Baylor College of Medicine</td>\n",
       "      <td>...</td>\n",
       "      <td>H-721</td>\n",
       "      <td>Jun-89</td>\n",
       "      <td>Dec-09</td>\n",
       "      <td>Feb-13</td>\n",
       "      <td>24-Mar-08</td>\n",
       "      <td>NaN</td>\n",
       "      <td>27-Sep-16</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00642057</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>255</th>\n",
       "      <td>256</td>\n",
       "      <td>NCT00590382</td>\n",
       "      <td>Emergency/Compassionate Use - Muscular VSD Occ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Approved for marketing</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Muscular|Ventricular|Septal|Defects|VSD</td>\n",
       "      <td>Device: AMPLATZER Muscular VSD Occluder</td>\n",
       "      <td>NaN</td>\n",
       "      <td>St. Jude Medical</td>\n",
       "      <td>...</td>\n",
       "      <td>AGA-005 - E/C|G990289</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>10-Jan-08</td>\n",
       "      <td>NaN</td>\n",
       "      <td>29-Jan-15</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00590382</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>256</th>\n",
       "      <td>257</td>\n",
       "      <td>NCT00584064</td>\n",
       "      <td>Emergency/Compassionate Use PFO Occluder</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Patent Foramen Ovale|PFO</td>\n",
       "      <td>Device: Device closure with the AMPLATZER PFO ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>St. Jude Medical</td>\n",
       "      <td>...</td>\n",
       "      <td>AGA-006 - E/C</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2-Jan-08</td>\n",
       "      <td>NaN</td>\n",
       "      <td>21-Jul-16</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00584064</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>257</th>\n",
       "      <td>258</td>\n",
       "      <td>NCT00580658</td>\n",
       "      <td>Humanitarian Device Exemption</td>\n",
       "      <td>Dystonia IRB</td>\n",
       "      <td>Approved for marketing</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Dystonia</td>\n",
       "      <td>Device: Medtronic Activa Gpi</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Vanderbilt University</td>\n",
       "      <td>...</td>\n",
       "      <td>60155</td>\n",
       "      <td>May-06</td>\n",
       "      <td>NaN</td>\n",
       "      <td>May-20</td>\n",
       "      <td>27-Dec-07</td>\n",
       "      <td>NaN</td>\n",
       "      <td>13-May-16</td>\n",
       "      <td>Vanderbilt University, Nashville, Tennessee, U...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00580658</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>258</th>\n",
       "      <td>259</td>\n",
       "      <td>NCT00575549</td>\n",
       "      <td>Prospective Analysis and Comparison of Stress ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Evaluation of Troponin I Levels</td>\n",
       "      <td>Other: Dobutamine: Perflutren Lipid Microsphere</td>\n",
       "      <td>NaN</td>\n",
       "      <td>University of Nebraska|Bristol-Myers Squibb</td>\n",
       "      <td>...</td>\n",
       "      <td>311-07-FB</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>18-Dec-07</td>\n",
       "      <td>NaN</td>\n",
       "      <td>23-Jul-12</td>\n",
       "      <td>University of Nebraska Medical Center, Omaha, ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00575549</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>259</th>\n",
       "      <td>260</td>\n",
       "      <td>NCT00528320</td>\n",
       "      <td>Clinical Evaluation of Cardiac Resynchronizati...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Approved for marketing</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Congestive Heart Failure (CHF)</td>\n",
       "      <td>Device: Ovatio CRT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ELA Medical, Inc.</td>\n",
       "      <td>...</td>\n",
       "      <td>ITAC06</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12-Sep-07</td>\n",
       "      <td>NaN</td>\n",
       "      <td>27-Nov-13</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00528320</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>260</th>\n",
       "      <td>261</td>\n",
       "      <td>NCT00520143</td>\n",
       "      <td>Alglucosidase Alfa Temporary Access Program</td>\n",
       "      <td>ATAP</td>\n",
       "      <td>Approved for marketing</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Glycogen Storage Disease Type II (GSD-II)|Pomp...</td>\n",
       "      <td>Biological: alglucosidase alfa (recombinant hu...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Genzyme, a Sanofi Company|Sanofi</td>\n",
       "      <td>...</td>\n",
       "      <td>AGLU03907</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>23-Aug-07</td>\n",
       "      <td>NaN</td>\n",
       "      <td>6-Feb-14</td>\n",
       "      <td>Sheffield, Alabama, United States|Anchorage, A...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00520143</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>261</th>\n",
       "      <td>262</td>\n",
       "      <td>NCT00508963</td>\n",
       "      <td>Compassionate Use of Sodium Stibogluconate (Pe...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Leishmaniasis, Cutaneous|Leishmaniasis, Mucocu...</td>\n",
       "      <td>Drug: sodium stibogluconate (Pentostam)</td>\n",
       "      <td>NaN</td>\n",
       "      <td>University of California, San Francisco</td>\n",
       "      <td>...</td>\n",
       "      <td>UCSF Infectious Diseases</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>30-Jul-07</td>\n",
       "      <td>NaN</td>\n",
       "      <td>15-Dec-14</td>\n",
       "      <td>University of CA at San Francisco Hospitals an...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00508963</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>262</th>\n",
       "      <td>263</td>\n",
       "      <td>NCT00499720</td>\n",
       "      <td>Aztreonam Lysine for Inhalation in Patients Wi...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Approved for marketing</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Cystic Fibrosis|Pseudomonas Aeruginosa Airway ...</td>\n",
       "      <td>Drug: Aztreonam Lysine for Inhalation</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Gilead Sciences</td>\n",
       "      <td>...</td>\n",
       "      <td>EA-US-205-0111</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>11-Jul-07</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2-Aug-11</td>\n",
       "      <td>Birmingham, Alabama, United States|Anchorage, ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00499720</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>263</th>\n",
       "      <td>264</td>\n",
       "      <td>NCT00484991</td>\n",
       "      <td>Sapropterin Expanded Access Program</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Approved for marketing</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Phenylketonuria</td>\n",
       "      <td>Drug: Sapropterin dihydrochloride</td>\n",
       "      <td>NaN</td>\n",
       "      <td>BioMarin Pharmaceutical</td>\n",
       "      <td>...</td>\n",
       "      <td>SEAP-001</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12-Jun-07</td>\n",
       "      <td>NaN</td>\n",
       "      <td>15-Apr-08</td>\n",
       "      <td>Los Angeles, California, United States|Orange,...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00484991</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>264</th>\n",
       "      <td>265</td>\n",
       "      <td>NCT00481559</td>\n",
       "      <td>Treatment Protocol of Voraxaze for Patients Ex...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Approved for marketing</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Neoplasms</td>\n",
       "      <td>Drug: Voraxaze (glucarpidase)</td>\n",
       "      <td>NaN</td>\n",
       "      <td>BTG International Inc.|CTI Clinical Trial and ...</td>\n",
       "      <td>...</td>\n",
       "      <td>PR001-CLN-pro016</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1-Jun-07</td>\n",
       "      <td>NaN</td>\n",
       "      <td>17-Jan-14</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00481559</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>265</th>\n",
       "      <td>266</td>\n",
       "      <td>NCT00457548</td>\n",
       "      <td>Phone Intervention for Alcohol (ETOH) Use in E...</td>\n",
       "      <td>DIAL</td>\n",
       "      <td>Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Alcoholic Intoxication|Wounds and Injuries</td>\n",
       "      <td>Behavioral: Brief Telephone Counseling for ris...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Rhode Island Hospital|Centers for Disease Cont...</td>\n",
       "      <td>...</td>\n",
       "      <td>R49/CCR123228-03</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>6-Apr-07</td>\n",
       "      <td>NaN</td>\n",
       "      <td>30-Mar-11</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00457548</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>266</th>\n",
       "      <td>267</td>\n",
       "      <td>NCT00454753</td>\n",
       "      <td>Korean Early Access Program</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Approved for marketing</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Leukemia</td>\n",
       "      <td>Drug: Dasatinib</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Bristol-Myers Squibb</td>\n",
       "      <td>...</td>\n",
       "      <td>CA180-109</td>\n",
       "      <td>May-07</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2-Apr-07</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12-May-10</td>\n",
       "      <td>Local Institution, Busan, Korea, Republic of|L...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00454753</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>267</th>\n",
       "      <td>268</td>\n",
       "      <td>NCT00438789</td>\n",
       "      <td>The Paroxysmal Nocturnal Hemoglobinuria Early ...</td>\n",
       "      <td>EMBRACE</td>\n",
       "      <td>Approved for marketing</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Hemoglobinuria, Paroxysmal</td>\n",
       "      <td>Drug: eculizumab</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Alexion Pharmaceuticals</td>\n",
       "      <td>...</td>\n",
       "      <td>C06-002</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>22-Feb-07</td>\n",
       "      <td>NaN</td>\n",
       "      <td>6-May-14</td>\n",
       "      <td>Anthony Botti, Livingston, New Jersey, United ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00438789</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>268</th>\n",
       "      <td>269</td>\n",
       "      <td>NCT00377065</td>\n",
       "      <td>Early Access of MK0518 in Combination With an ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Approved for marketing</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>HIV Infections</td>\n",
       "      <td>Drug: raltegravir</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Merck Sharp &amp; Dohme Corp.</td>\n",
       "      <td>...</td>\n",
       "      <td>0518-023|MK0518-023|2006_031</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>15-Sep-06</td>\n",
       "      <td>NaN</td>\n",
       "      <td>22-Apr-16</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00377065</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>269</th>\n",
       "      <td>270</td>\n",
       "      <td>NCT00338442</td>\n",
       "      <td>Safety and Efficacy of Varicella Zoster Immune...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Approved for marketing</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Varicella</td>\n",
       "      <td>Drug: VariZIG™</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Cangene Corporation</td>\n",
       "      <td>...</td>\n",
       "      <td>VZ-009</td>\n",
       "      <td>Feb-06</td>\n",
       "      <td>Dec-09</td>\n",
       "      <td>Dec-09</td>\n",
       "      <td>20-Jun-06</td>\n",
       "      <td>NaN</td>\n",
       "      <td>4-Apr-13</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00338442</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>270</th>\n",
       "      <td>271</td>\n",
       "      <td>NCT00338247</td>\n",
       "      <td>EAP (Expanded Access Protocol) Of Lapatinib Co...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Approved for marketing</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Neoplasms, Breast</td>\n",
       "      <td>Drug: lapatinib + capecitabine</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>...</td>\n",
       "      <td>EGF103659</td>\n",
       "      <td>Jul-06</td>\n",
       "      <td>Mar-15</td>\n",
       "      <td>Mar-15</td>\n",
       "      <td>20-Jun-06</td>\n",
       "      <td>NaN</td>\n",
       "      <td>6-Apr-16</td>\n",
       "      <td>Novartis Investigative Site, Huntsville, Alaba...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00338247</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>271</th>\n",
       "      <td>272</td>\n",
       "      <td>NCT00293098</td>\n",
       "      <td>Compassionate Use of Deferiprone for Patients ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Approved for marketing</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Iron Overload</td>\n",
       "      <td>Drug: deferiprone</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Children's Hospital of Philadelphia|ApoPharma</td>\n",
       "      <td>...</td>\n",
       "      <td>2006-2-4700</td>\n",
       "      <td>Mar-06</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>17-Feb-06</td>\n",
       "      <td>NaN</td>\n",
       "      <td>9-Feb-12</td>\n",
       "      <td>The Children's Hospital of Philadelphia, Phila...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00293098</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>272</th>\n",
       "      <td>273</td>\n",
       "      <td>NCT00291811</td>\n",
       "      <td>Access Program for Use of AMD3100 to Increase ...</td>\n",
       "      <td>CUP</td>\n",
       "      <td>Approved for marketing</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Autologous Stem Cell Transplant</td>\n",
       "      <td>Drug: AMD3100 + G-CSF</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Genzyme, a Sanofi Company|Sanofi</td>\n",
       "      <td>...</td>\n",
       "      <td>AMD3100-CUP001</td>\n",
       "      <td>Oct-03</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>15-Feb-06</td>\n",
       "      <td>NaN</td>\n",
       "      <td>11-Feb-14</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00291811</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>273</th>\n",
       "      <td>274</td>\n",
       "      <td>NCT00245739</td>\n",
       "      <td>TMC114-C226: An Early Access Program to Evalua...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Approved for marketing</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>HIV Infections</td>\n",
       "      <td>Drug: TMC-114</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tibotec Pharmaceuticals, Ireland</td>\n",
       "      <td>...</td>\n",
       "      <td>CR006304|TMC114-C226</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>28-Oct-05</td>\n",
       "      <td>NaN</td>\n",
       "      <td>11-Apr-14</td>\n",
       "      <td>Anniston, Alabama, United States|Birmingham, A...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00245739</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>274</th>\n",
       "      <td>275</td>\n",
       "      <td>NCT00244686</td>\n",
       "      <td>This Record Contains Information About the Mep...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Hypereosinophilic Syndrome</td>\n",
       "      <td>Drug: Mepolizumab</td>\n",
       "      <td>NaN</td>\n",
       "      <td>GlaxoSmithKline</td>\n",
       "      <td>...</td>\n",
       "      <td>MHE104317</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>27-Oct-05</td>\n",
       "      <td>NaN</td>\n",
       "      <td>13-Apr-18</td>\n",
       "      <td>GSK Investigational Site, Birmingham, Alabama,...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00244686</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>275</th>\n",
       "      <td>276</td>\n",
       "      <td>NCT00130897</td>\n",
       "      <td>Treatment Use Study With Sunitinib (SU011248) ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Approved for marketing</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Carcinoma, Renal Cell</td>\n",
       "      <td>Drug: Sutent</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>...</td>\n",
       "      <td>A6181037</td>\n",
       "      <td>Jul-05</td>\n",
       "      <td>Nov-11</td>\n",
       "      <td>Nov-11</td>\n",
       "      <td>16-Aug-05</td>\n",
       "      <td>NaN</td>\n",
       "      <td>9-Mar-12</td>\n",
       "      <td>Pfizer Investigational Site, Scottsdale, Arizo...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00130897</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>276</th>\n",
       "      <td>277</td>\n",
       "      <td>NCT00097799</td>\n",
       "      <td>Tipranavir Expanded Access Program (EAP) in PI...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Approved for marketing</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>HIV Infections</td>\n",
       "      <td>Drug: Tipranavir|Drug: Ritonavir</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Boehringer Ingelheim</td>\n",
       "      <td>...</td>\n",
       "      <td>1182.7</td>\n",
       "      <td>Dec-04</td>\n",
       "      <td>Aug-05</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1-Dec-04</td>\n",
       "      <td>NaN</td>\n",
       "      <td>30-Nov-16</td>\n",
       "      <td>1182.70.127 Health Services Center, Inc., Anni...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00097799</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>277</th>\n",
       "      <td>278</td>\n",
       "      <td>NCT00094029</td>\n",
       "      <td>A Treatment Protocol for Patients With Gastroi...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Approved for marketing</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Gastrointestinal Neoplasm</td>\n",
       "      <td>Drug: Sutent</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>...</td>\n",
       "      <td>A6181036</td>\n",
       "      <td>Sep-04</td>\n",
       "      <td>Oct-11</td>\n",
       "      <td>Oct-11</td>\n",
       "      <td>11-Oct-04</td>\n",
       "      <td>NaN</td>\n",
       "      <td>9-Mar-12</td>\n",
       "      <td>Pfizer Investigational Site, Duarte, Californi...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00094029</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>278</th>\n",
       "      <td>279</td>\n",
       "      <td>NCT00074919</td>\n",
       "      <td>Expanded Access Use of Myozyme (Alglucosidase ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Approved for marketing</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Glycogen Storage Disease Type II|Glycogenosis 2</td>\n",
       "      <td>Biological: alglucosidase alfa</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Genzyme, a Sanofi Company|Sanofi</td>\n",
       "      <td>...</td>\n",
       "      <td>AGLU02203</td>\n",
       "      <td>Dec-03</td>\n",
       "      <td>Feb-07</td>\n",
       "      <td>Feb-07</td>\n",
       "      <td>25-Dec-03</td>\n",
       "      <td>NaN</td>\n",
       "      <td>5-Feb-14</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00074919</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>279</th>\n",
       "      <td>280</td>\n",
       "      <td>NCT00062660</td>\n",
       "      <td>Tipranavir in Patients With Progressive, Syste...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Approved for marketing</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>HIV Infections</td>\n",
       "      <td>Drug: Tipranavir</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Boehringer Ingelheim</td>\n",
       "      <td>...</td>\n",
       "      <td>1182.58</td>\n",
       "      <td>May-03</td>\n",
       "      <td>Apr-14</td>\n",
       "      <td>Apr-14</td>\n",
       "      <td>12-Jun-03</td>\n",
       "      <td>NaN</td>\n",
       "      <td>30-Nov-16</td>\n",
       "      <td>1182.58.31, Scottsdale, Arizona, United States...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00062660</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>280</th>\n",
       "      <td>281</td>\n",
       "      <td>NCT00042393</td>\n",
       "      <td>An Open-Label Program of Adefovir Dipivoxil in...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Approved for marketing</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Chronic Hepatitis B</td>\n",
       "      <td>Drug: Adefovir Dipivoxil</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Gilead Sciences</td>\n",
       "      <td>...</td>\n",
       "      <td>GS-01-550</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1-Aug-02</td>\n",
       "      <td>NaN</td>\n",
       "      <td>7-Jan-14</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00042393</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>281</th>\n",
       "      <td>282</td>\n",
       "      <td>NCT00040625</td>\n",
       "      <td>ALIMTA (Pemetrexed) Alone or in Combination Wi...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Approved for marketing</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Mesothelioma</td>\n",
       "      <td>Drug: Pemetrexed|Drug: Cisplatin</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Eli Lilly and Company</td>\n",
       "      <td>...</td>\n",
       "      <td>6093|H3E-US-JMFE</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>4-Jul-02</td>\n",
       "      <td>NaN</td>\n",
       "      <td>15-Mar-07</td>\n",
       "      <td>For additional information regarding investiga...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00040625</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>282 rows × 27 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     Rank   NCT Number                                              Title  \\\n",
       "0       1  NCT03564964  Expanded Access to Provide SUVN-502 for the Tr...   \n",
       "1       2  NCT03561194  Omegaven Protocol:Intermediate Size Patient Po...   \n",
       "2       3  NCT03559686  Named Patient Program With Certolizumab Pegol ...   \n",
       "3       4  NCT03559673  Compassionate Use Program With Lacosamide in P...   \n",
       "4       5  NCT03559660  CUP Certolizumab Pegol (CDP-870) in Adults Suf...   \n",
       "5       6  NCT03544060  Volanesorsen Early Access Program for Patients...   \n",
       "6       7  NCT03539393  Expanded Access Program for Patients With Migr...   \n",
       "7       8  NCT03539380  TRx0237 for the Treatment of Mild-Moderate Alz...   \n",
       "8       9  NCT03537807  Expanded Access Protocol of BHV-0223 for Patie...   \n",
       "9      10  NCT03533361  Expanded Access Program With Lenvatinib for th...   \n",
       "10     11  NCT03532516  Compassionate Use Program With Brivaracetam fo...   \n",
       "11     12  NCT03503890         Expanded Access to Rovalpituzumab Tesirine   \n",
       "12     13  NCT03501940  F18 DCFPyL PET/CT in Imaging Participants With...   \n",
       "13     14  NCT03501615  An Early Access Programme for Moxetumomab Pasu...   \n",
       "14     15  NCT03493165  Expanded Access to Everolimus, for an Individu...   \n",
       "15     16  NCT03493152  Expanded Access to Everolimus, for an Individu...   \n",
       "16     17  NCT03492489  Expanded Access Protocol for Cemiplimab in Met...   \n",
       "17     18  NCT03462810  GSK1265744 (Cabotegravir, CAB) for Named Patie...   \n",
       "18     19  NCT03439475                    AMG 714 Expanded Access Program   \n",
       "19     20  NCT03433807  Expanded Access Program for Idebenone in Parti...   \n",
       "20     21  NCT03433131  Expanded Access Program to Provide Treatment W...   \n",
       "21     22  NCT03420430  Expanded Access to Provide GL-ONC1 for the Tre...   \n",
       "22     23  NCT03419949  Comparison of Oral Lamotrigine and Oral Pregab...   \n",
       "23     24  NCT03414489  Expanded Access for the Treatment of Advanced ...   \n",
       "24     25  NCT03412539  Mechanism of Effectiveness of Neurosurgery Tre...   \n",
       "25     26  NCT03409081  Early Access Program (EAP) of Gilteritinib (AS...   \n",
       "26     27  NCT03400098        ATTR Expanded Access Program (EAP) by Ionis   \n",
       "27     28  NCT03395769  Individual Patient Expanded Access for AB-SA01...   \n",
       "28     29  NCT03395743  Individual Patient Expanded Access for AB-PA01...   \n",
       "29     30  NCT03386071  Compassionate Use: Progressive Metastatic Cast...   \n",
       "..    ...          ...                                                ...   \n",
       "252   253  NCT00650026  Early Access Program of the Safety of Human An...   \n",
       "253   254  NCT00649545  Study of the Human Anti-TNF Monoclonal Antibod...   \n",
       "254   255  NCT00642057  Compassionate Use of Tetrabenazine in the Trea...   \n",
       "255   256  NCT00590382  Emergency/Compassionate Use - Muscular VSD Occ...   \n",
       "256   257  NCT00584064           Emergency/Compassionate Use PFO Occluder   \n",
       "257   258  NCT00580658                      Humanitarian Device Exemption   \n",
       "258   259  NCT00575549  Prospective Analysis and Comparison of Stress ...   \n",
       "259   260  NCT00528320  Clinical Evaluation of Cardiac Resynchronizati...   \n",
       "260   261  NCT00520143        Alglucosidase Alfa Temporary Access Program   \n",
       "261   262  NCT00508963  Compassionate Use of Sodium Stibogluconate (Pe...   \n",
       "262   263  NCT00499720  Aztreonam Lysine for Inhalation in Patients Wi...   \n",
       "263   264  NCT00484991                Sapropterin Expanded Access Program   \n",
       "264   265  NCT00481559  Treatment Protocol of Voraxaze for Patients Ex...   \n",
       "265   266  NCT00457548  Phone Intervention for Alcohol (ETOH) Use in E...   \n",
       "266   267  NCT00454753                        Korean Early Access Program   \n",
       "267   268  NCT00438789  The Paroxysmal Nocturnal Hemoglobinuria Early ...   \n",
       "268   269  NCT00377065  Early Access of MK0518 in Combination With an ...   \n",
       "269   270  NCT00338442  Safety and Efficacy of Varicella Zoster Immune...   \n",
       "270   271  NCT00338247  EAP (Expanded Access Protocol) Of Lapatinib Co...   \n",
       "271   272  NCT00293098  Compassionate Use of Deferiprone for Patients ...   \n",
       "272   273  NCT00291811  Access Program for Use of AMD3100 to Increase ...   \n",
       "273   274  NCT00245739  TMC114-C226: An Early Access Program to Evalua...   \n",
       "274   275  NCT00244686  This Record Contains Information About the Mep...   \n",
       "275   276  NCT00130897  Treatment Use Study With Sunitinib (SU011248) ...   \n",
       "276   277  NCT00097799  Tipranavir Expanded Access Program (EAP) in PI...   \n",
       "277   278  NCT00094029  A Treatment Protocol for Patients With Gastroi...   \n",
       "278   279  NCT00074919  Expanded Access Use of Myozyme (Alglucosidase ...   \n",
       "279   280  NCT00062660  Tipranavir in Patients With Progressive, Syste...   \n",
       "280   281  NCT00042393  An Open-Label Program of Adefovir Dipivoxil in...   \n",
       "281   282  NCT00040625  ALIMTA (Pemetrexed) Alone or in Combination Wi...   \n",
       "\n",
       "          Acronym                  Status         Study Results  \\\n",
       "0        SUVN-502               Available  No Results Available   \n",
       "1             NaN               Available  No Results Available   \n",
       "2             NaN               Available  No Results Available   \n",
       "3             NaN               Available  No Results Available   \n",
       "4             NaN               Available  No Results Available   \n",
       "5             NaN               Available  No Results Available   \n",
       "6             NaN               Available  No Results Available   \n",
       "7             NaN               Available  No Results Available   \n",
       "8             NaN               Available  No Results Available   \n",
       "9             NaN  Approved for marketing  No Results Available   \n",
       "10            NaN               Available  No Results Available   \n",
       "11            NaN               Available  No Results Available   \n",
       "12            NaN               Available  No Results Available   \n",
       "13           MOXE               Available  No Results Available   \n",
       "14            NaN               Available  No Results Available   \n",
       "15            NaN               Available  No Results Available   \n",
       "16            NaN               Available  No Results Available   \n",
       "17            NaN               Available  No Results Available   \n",
       "18            NaN               Available  No Results Available   \n",
       "19            NaN               Available  No Results Available   \n",
       "20            NaN               Available  No Results Available   \n",
       "21            NaN               Available  No Results Available   \n",
       "22            NaN               Available  No Results Available   \n",
       "23            NaN               Available  No Results Available   \n",
       "24            NaN               Available  No Results Available   \n",
       "25            NaN               Available  No Results Available   \n",
       "26            NaN               Available  No Results Available   \n",
       "27            NaN               Available  No Results Available   \n",
       "28            NaN               Available  No Results Available   \n",
       "29            NaN               Available  No Results Available   \n",
       "..            ...                     ...                   ...   \n",
       "252         ReAct  Approved for marketing  No Results Available   \n",
       "253        CanAct  Approved for marketing  No Results Available   \n",
       "254           TBZ               Available  No Results Available   \n",
       "255           NaN  Approved for marketing  No Results Available   \n",
       "256           NaN               Available  No Results Available   \n",
       "257  Dystonia IRB  Approved for marketing  No Results Available   \n",
       "258           NaN               Available  No Results Available   \n",
       "259           NaN  Approved for marketing  No Results Available   \n",
       "260          ATAP  Approved for marketing  No Results Available   \n",
       "261           NaN               Available  No Results Available   \n",
       "262           NaN  Approved for marketing  No Results Available   \n",
       "263           NaN  Approved for marketing  No Results Available   \n",
       "264           NaN  Approved for marketing  No Results Available   \n",
       "265          DIAL               Available  No Results Available   \n",
       "266           NaN  Approved for marketing  No Results Available   \n",
       "267       EMBRACE  Approved for marketing  No Results Available   \n",
       "268           NaN  Approved for marketing  No Results Available   \n",
       "269           NaN  Approved for marketing  No Results Available   \n",
       "270           NaN  Approved for marketing  No Results Available   \n",
       "271           NaN  Approved for marketing  No Results Available   \n",
       "272           CUP  Approved for marketing  No Results Available   \n",
       "273           NaN  Approved for marketing  No Results Available   \n",
       "274           NaN               Available  No Results Available   \n",
       "275           NaN  Approved for marketing  No Results Available   \n",
       "276           NaN  Approved for marketing  No Results Available   \n",
       "277           NaN  Approved for marketing  No Results Available   \n",
       "278           NaN  Approved for marketing  No Results Available   \n",
       "279           NaN  Approved for marketing  No Results Available   \n",
       "280           NaN  Approved for marketing  No Results Available   \n",
       "281           NaN  Approved for marketing  No Results Available   \n",
       "\n",
       "                                            Conditions  \\\n",
       "0       Alzheimer Disease|Dementia|Cognition Disorders   \n",
       "1        Parenteral Nutrition Associated Liver Disease   \n",
       "2                                 Rheumatoid Arthritis   \n",
       "3                                  Epilepsies, Partial   \n",
       "4                                      Crohn's Disease   \n",
       "5                             Familial Chylomicronemia   \n",
       "6                            Migraine|Cluster Headache   \n",
       "7                                    Alzheimer Disease   \n",
       "8    Amyotrophic Lateral Sclerosis|ALS|Lou Gehrig D...   \n",
       "9                                       Thyroid Cancer   \n",
       "10                                            Epilepsy   \n",
       "11                              Small Cell Lung Cancer   \n",
       "12   Prostate Adenocarcinoma|PSA Level Greater Than...   \n",
       "13             Relapsed/Refractory Hairy Cell Leukemia   \n",
       "14                                                 NaN   \n",
       "15                      Gastrointestinal Stromal Tumor   \n",
       "16                   Cutaneous Squamous Cell Carcinoma   \n",
       "17             Infection, Human Immunodeficiency Virus   \n",
       "18                                                 NaN   \n",
       "19                         Duchenne Muscular Dystrophy   \n",
       "20   Narcolepsy Without Cataplexy|Narcolepsy With C...   \n",
       "21   Advanced Stage Cancer (Solid Tumor Disease for...   \n",
       "22   Acute and Chronic Pain Following Modified Radi...   \n",
       "23   Cholangiocarcinoma|Cholangiocarcinoma Non-rese...   \n",
       "24                                    Oncology Problem   \n",
       "25   Acute Myeloid Leukemia (AML)|FMS-like Tyrosine...   \n",
       "26                             Amyloidosis, Hereditary   \n",
       "27                                                 NaN   \n",
       "28                                                 NaN   \n",
       "29   Progressive Metastatic Castrate Resistant Pros...   \n",
       "..                                                 ...   \n",
       "252                               Rheumatoid Arthritis   \n",
       "253                               Rheumatoid Arthritis   \n",
       "254                    Hyperkinetic Movement Disorders   \n",
       "255            Muscular|Ventricular|Septal|Defects|VSD   \n",
       "256                           Patent Foramen Ovale|PFO   \n",
       "257                                           Dystonia   \n",
       "258                    Evaluation of Troponin I Levels   \n",
       "259                     Congestive Heart Failure (CHF)   \n",
       "260  Glycogen Storage Disease Type II (GSD-II)|Pomp...   \n",
       "261  Leishmaniasis, Cutaneous|Leishmaniasis, Mucocu...   \n",
       "262  Cystic Fibrosis|Pseudomonas Aeruginosa Airway ...   \n",
       "263                                    Phenylketonuria   \n",
       "264                                          Neoplasms   \n",
       "265         Alcoholic Intoxication|Wounds and Injuries   \n",
       "266                                           Leukemia   \n",
       "267                         Hemoglobinuria, Paroxysmal   \n",
       "268                                     HIV Infections   \n",
       "269                                          Varicella   \n",
       "270                                  Neoplasms, Breast   \n",
       "271                                      Iron Overload   \n",
       "272                    Autologous Stem Cell Transplant   \n",
       "273                                     HIV Infections   \n",
       "274                         Hypereosinophilic Syndrome   \n",
       "275                              Carcinoma, Renal Cell   \n",
       "276                                     HIV Infections   \n",
       "277                          Gastrointestinal Neoplasm   \n",
       "278    Glycogen Storage Disease Type II|Glycogenosis 2   \n",
       "279                                     HIV Infections   \n",
       "280                                Chronic Hepatitis B   \n",
       "281                                       Mesothelioma   \n",
       "\n",
       "                                         Interventions  Outcome Measures  \\\n",
       "0                                       Drug: SUVN-502               NaN   \n",
       "1                                      Other: Omegaven               NaN   \n",
       "2                             Drug: Certolizumab Pegol               NaN   \n",
       "3                                     Drug: Lacosamide               NaN   \n",
       "4                             Drug: Certolizumab Pegol               NaN   \n",
       "5                                   Drug: Volanesorsen               NaN   \n",
       "6                                   Drug: Fremanezumab               NaN   \n",
       "7                                        Drug: TRx0237               NaN   \n",
       "8                                       Drug: Riluzole               NaN   \n",
       "9                                     Drug: Lenvatinib               NaN   \n",
       "10                                  Drug: Brivaracetam               NaN   \n",
       "11                       Drug: rovalpituzumab tesirine               NaN   \n",
       "12   Procedure: Computed Tomography|Radiation: Fluo...               NaN   \n",
       "13                         Drug: Moxetumomab Pasudotox               NaN   \n",
       "14                                    Drug: Everolimus               NaN   \n",
       "15                                    Drug: Everolimus               NaN   \n",
       "16                                    Drug: cemiplimab               NaN   \n",
       "17                             Drug: cabotegravir, CAB               NaN   \n",
       "18                                 Biological: AMG 714               NaN   \n",
       "19                                     Drug: Idebenone               NaN   \n",
       "20                                    Drug: Pitolisant               NaN   \n",
       "21                                 Biological: GL-ONC1               NaN   \n",
       "22   Drug: oral lamotrigine 100 mg|Drug: oral prega...               NaN   \n",
       "23                                     Drug: ABC294640               NaN   \n",
       "24                                                 NaN               NaN   \n",
       "25                                  Drug: gilteritinib               NaN   \n",
       "26                                     Drug: Inotersen               NaN   \n",
       "27                                 Biological: AB-SA01               NaN   \n",
       "28                                 Biological: AB-PA01               NaN   \n",
       "29                               Drug: Trametinib 2 mg               NaN   \n",
       "..                                                 ...               ...   \n",
       "252                             Biological: adalimumab               NaN   \n",
       "253                             Biological: adalimumab               NaN   \n",
       "254                                Drug: tetrabenazine               NaN   \n",
       "255            Device: AMPLATZER Muscular VSD Occluder               NaN   \n",
       "256  Device: Device closure with the AMPLATZER PFO ...               NaN   \n",
       "257                       Device: Medtronic Activa Gpi               NaN   \n",
       "258    Other: Dobutamine: Perflutren Lipid Microsphere               NaN   \n",
       "259                                 Device: Ovatio CRT               NaN   \n",
       "260  Biological: alglucosidase alfa (recombinant hu...               NaN   \n",
       "261            Drug: sodium stibogluconate (Pentostam)               NaN   \n",
       "262              Drug: Aztreonam Lysine for Inhalation               NaN   \n",
       "263                  Drug: Sapropterin dihydrochloride               NaN   \n",
       "264                      Drug: Voraxaze (glucarpidase)               NaN   \n",
       "265  Behavioral: Brief Telephone Counseling for ris...               NaN   \n",
       "266                                    Drug: Dasatinib               NaN   \n",
       "267                                   Drug: eculizumab               NaN   \n",
       "268                                  Drug: raltegravir               NaN   \n",
       "269                                     Drug: VariZIG™               NaN   \n",
       "270                     Drug: lapatinib + capecitabine               NaN   \n",
       "271                                  Drug: deferiprone               NaN   \n",
       "272                              Drug: AMD3100 + G-CSF               NaN   \n",
       "273                                      Drug: TMC-114               NaN   \n",
       "274                                  Drug: Mepolizumab               NaN   \n",
       "275                                       Drug: Sutent               NaN   \n",
       "276                   Drug: Tipranavir|Drug: Ritonavir               NaN   \n",
       "277                                       Drug: Sutent               NaN   \n",
       "278                     Biological: alglucosidase alfa               NaN   \n",
       "279                                   Drug: Tipranavir               NaN   \n",
       "280                           Drug: Adefovir Dipivoxil               NaN   \n",
       "281                   Drug: Pemetrexed|Drug: Cisplatin               NaN   \n",
       "\n",
       "                                 Sponsor/Collaborators  \\\n",
       "0                          Suven Life Sciences Limited   \n",
       "1                      Doctors Hospital at Renaissance   \n",
       "2                    UCB Biopharma S.P.R.L.|UCB Pharma   \n",
       "3                    UCB Biopharma S.P.R.L.|UCB Pharma   \n",
       "4                    UCB Biopharma S.P.R.L.|UCB Pharma   \n",
       "5                   Akcea Therapeutics|CaligorRx, Inc.   \n",
       "6    Teva Branded Pharmaceutical Products, R&D Inc....   \n",
       "7                               TauRx Therapeutics Ltd   \n",
       "8                       Biohaven Pharmaceuticals, Inc.   \n",
       "9                                           Eisai Inc.   \n",
       "10                   UCB Biopharma S.P.R.L.|UCB Pharma   \n",
       "11                                              AbbVie   \n",
       "12                   Andrei Iagaru|Stanford University   \n",
       "13                                         AstraZeneca   \n",
       "14   The University of Texas Health Science Center ...   \n",
       "15   The University of Texas Health Science Center ...   \n",
       "16                    Regeneron Pharmaceuticals|Sanofi   \n",
       "17                                     ViiV Healthcare   \n",
       "18                                               Amgen   \n",
       "19                            Santhera Pharmaceuticals   \n",
       "20                            Harmony Biosciences, LLC   \n",
       "21                                 Genelux Corporation   \n",
       "22                                   Assiut University   \n",
       "23                           RedHill Biopharma Limited   \n",
       "24   Tel-Aviv Sourasky Medical Center|University of...   \n",
       "25   Astellas Pharma Global Development, Inc.|Astel...   \n",
       "26      Ionis Pharmaceuticals, Inc.|Clinigen Group PLC   \n",
       "27                    AmpliPhi Biosciences Corporation   \n",
       "28                    AmpliPhi Biosciences Corporation   \n",
       "29        Jonsson Comprehensive Cancer Center|Novartis   \n",
       "..                                                 ...   \n",
       "252                                             Abbott   \n",
       "253                                             Abbott   \n",
       "254        Christine Hunter|Baylor College of Medicine   \n",
       "255                                   St. Jude Medical   \n",
       "256                                   St. Jude Medical   \n",
       "257                              Vanderbilt University   \n",
       "258        University of Nebraska|Bristol-Myers Squibb   \n",
       "259                                  ELA Medical, Inc.   \n",
       "260                   Genzyme, a Sanofi Company|Sanofi   \n",
       "261            University of California, San Francisco   \n",
       "262                                    Gilead Sciences   \n",
       "263                            BioMarin Pharmaceutical   \n",
       "264  BTG International Inc.|CTI Clinical Trial and ...   \n",
       "265  Rhode Island Hospital|Centers for Disease Cont...   \n",
       "266                               Bristol-Myers Squibb   \n",
       "267                            Alexion Pharmaceuticals   \n",
       "268                          Merck Sharp & Dohme Corp.   \n",
       "269                                Cangene Corporation   \n",
       "270                                           Novartis   \n",
       "271      Children's Hospital of Philadelphia|ApoPharma   \n",
       "272                   Genzyme, a Sanofi Company|Sanofi   \n",
       "273                   Tibotec Pharmaceuticals, Ireland   \n",
       "274                                    GlaxoSmithKline   \n",
       "275                                             Pfizer   \n",
       "276                               Boehringer Ingelheim   \n",
       "277                                             Pfizer   \n",
       "278                   Genzyme, a Sanofi Company|Sanofi   \n",
       "279                               Boehringer Ingelheim   \n",
       "280                                    Gilead Sciences   \n",
       "281                              Eli Lilly and Company   \n",
       "\n",
       "                        ...                       \\\n",
       "0                       ...                        \n",
       "1                       ...                        \n",
       "2                       ...                        \n",
       "3                       ...                        \n",
       "4                       ...                        \n",
       "5                       ...                        \n",
       "6                       ...                        \n",
       "7                       ...                        \n",
       "8                       ...                        \n",
       "9                       ...                        \n",
       "10                      ...                        \n",
       "11                      ...                        \n",
       "12                      ...                        \n",
       "13                      ...                        \n",
       "14                      ...                        \n",
       "15                      ...                        \n",
       "16                      ...                        \n",
       "17                      ...                        \n",
       "18                      ...                        \n",
       "19                      ...                        \n",
       "20                      ...                        \n",
       "21                      ...                        \n",
       "22                      ...                        \n",
       "23                      ...                        \n",
       "24                      ...                        \n",
       "25                      ...                        \n",
       "26                      ...                        \n",
       "27                      ...                        \n",
       "28                      ...                        \n",
       "29                      ...                        \n",
       "..                      ...                        \n",
       "252                     ...                        \n",
       "253                     ...                        \n",
       "254                     ...                        \n",
       "255                     ...                        \n",
       "256                     ...                        \n",
       "257                     ...                        \n",
       "258                     ...                        \n",
       "259                     ...                        \n",
       "260                     ...                        \n",
       "261                     ...                        \n",
       "262                     ...                        \n",
       "263                     ...                        \n",
       "264                     ...                        \n",
       "265                     ...                        \n",
       "266                     ...                        \n",
       "267                     ...                        \n",
       "268                     ...                        \n",
       "269                     ...                        \n",
       "270                     ...                        \n",
       "271                     ...                        \n",
       "272                     ...                        \n",
       "273                     ...                        \n",
       "274                     ...                        \n",
       "275                     ...                        \n",
       "276                     ...                        \n",
       "277                     ...                        \n",
       "278                     ...                        \n",
       "279                     ...                        \n",
       "280                     ...                        \n",
       "281                     ...                        \n",
       "\n",
       "                                  Other IDs Start Date  \\\n",
       "0                                EAP1502HT6        NaN   \n",
       "1                                         2        NaN   \n",
       "2                                    RA0039        NaN   \n",
       "3                                    EP0072        NaN   \n",
       "4                                    C87092        NaN   \n",
       "5                               ISIS 304801        NaN   \n",
       "6                         TV48125-CNS-80005        NaN   \n",
       "7                               TRx-237-040        NaN   \n",
       "8                               BHV0223-401        NaN   \n",
       "9                            E7080-M001-603        NaN   \n",
       "10                                   N01317        NaN   \n",
       "11                                  C18-915        NaN   \n",
       "12        PROS0083|NCI-2018-00479|IRB-42701        NaN   \n",
       "13                              D3143R00002        NaN   \n",
       "14                            CTMS# 18-0020        NaN   \n",
       "15                            CTMS# 18-0019        NaN   \n",
       "16                          R2810-ONC-17103        NaN   \n",
       "17                                   205741        NaN   \n",
       "18           AMG714 Expanded Access Program        NaN   \n",
       "19                              SNT-EAP-002        NaN   \n",
       "20                           HBS-101-CL-001        NaN   \n",
       "21                              GL-ONC1-021        NaN   \n",
       "22           Comparison of oral lamotrigine        NaN   \n",
       "23                               ABC-108-EA        NaN   \n",
       "24                        TASMC-0354-17-TLV        NaN   \n",
       "25                             2215-CL-9200        NaN   \n",
       "26                          ISIS 420915-CS5        NaN   \n",
       "27                            AB-SA01-EAP01        NaN   \n",
       "28                            AB-PA01-EAP01        NaN   \n",
       "29   17-001886|Compassionate Use Trametinib        NaN   \n",
       "..                                      ...        ...   \n",
       "252                                 M03-583        NaN   \n",
       "253                                 M02-574        NaN   \n",
       "254                                   H-721     Jun-89   \n",
       "255                   AGA-005 - E/C|G990289        NaN   \n",
       "256                           AGA-006 - E/C        NaN   \n",
       "257                                   60155     May-06   \n",
       "258                               311-07-FB        NaN   \n",
       "259                                  ITAC06        NaN   \n",
       "260                               AGLU03907        NaN   \n",
       "261                UCSF Infectious Diseases        NaN   \n",
       "262                          EA-US-205-0111        NaN   \n",
       "263                                SEAP-001        NaN   \n",
       "264                        PR001-CLN-pro016        NaN   \n",
       "265                        R49/CCR123228-03        NaN   \n",
       "266                               CA180-109     May-07   \n",
       "267                                 C06-002        NaN   \n",
       "268            0518-023|MK0518-023|2006_031        NaN   \n",
       "269                                  VZ-009     Feb-06   \n",
       "270                               EGF103659     Jul-06   \n",
       "271                             2006-2-4700     Mar-06   \n",
       "272                          AMD3100-CUP001     Oct-03   \n",
       "273                    CR006304|TMC114-C226        NaN   \n",
       "274                               MHE104317        NaN   \n",
       "275                                A6181037     Jul-05   \n",
       "276                                  1182.7     Dec-04   \n",
       "277                                A6181036     Sep-04   \n",
       "278                               AGLU02203     Dec-03   \n",
       "279                                 1182.58     May-03   \n",
       "280                               GS-01-550        NaN   \n",
       "281                        6093|H3E-US-JMFE        NaN   \n",
       "\n",
       "     Primary Completion Date  Completion Date First Posted  \\\n",
       "0                        NaN              NaN    21-Jun-18   \n",
       "1                        NaN              NaN    19-Jun-18   \n",
       "2                        NaN              NaN    18-Jun-18   \n",
       "3                        NaN              NaN    18-Jun-18   \n",
       "4                        NaN              NaN    18-Jun-18   \n",
       "5                        NaN              NaN     1-Jun-18   \n",
       "6                        NaN              NaN    28-May-18   \n",
       "7                        NaN              NaN    28-May-18   \n",
       "8                        NaN              NaN    25-May-18   \n",
       "9                        NaN              NaN    23-May-18   \n",
       "10                       NaN              NaN    22-May-18   \n",
       "11                       NaN              NaN    20-Apr-18   \n",
       "12                       NaN              NaN    18-Apr-18   \n",
       "13                       NaN              NaN    18-Apr-18   \n",
       "14                       NaN              NaN    10-Apr-18   \n",
       "15                       NaN              NaN    10-Apr-18   \n",
       "16                       NaN              NaN    10-Apr-18   \n",
       "17                       NaN              NaN    13-Mar-18   \n",
       "18                       NaN              NaN    20-Feb-18   \n",
       "19                       NaN              NaN    15-Feb-18   \n",
       "20                       NaN              NaN    14-Feb-18   \n",
       "21                       NaN              NaN     2-Feb-18   \n",
       "22                       NaN              NaN     2-Feb-18   \n",
       "23                       NaN              NaN    30-Jan-18   \n",
       "24                       NaN              NaN    26-Jan-18   \n",
       "25                       NaN              NaN    24-Jan-18   \n",
       "26                       NaN              NaN    17-Jan-18   \n",
       "27                       NaN              NaN    10-Jan-18   \n",
       "28                       NaN              NaN    10-Jan-18   \n",
       "29                       NaN              NaN    29-Dec-17   \n",
       "..                       ...              ...          ...   \n",
       "252                      NaN              NaN     1-Apr-08   \n",
       "253                      NaN              NaN     1-Apr-08   \n",
       "254                   Dec-09           Feb-13    24-Mar-08   \n",
       "255                      NaN              NaN    10-Jan-08   \n",
       "256                      NaN              NaN     2-Jan-08   \n",
       "257                      NaN           May-20    27-Dec-07   \n",
       "258                      NaN              NaN    18-Dec-07   \n",
       "259                      NaN              NaN    12-Sep-07   \n",
       "260                      NaN              NaN    23-Aug-07   \n",
       "261                      NaN              NaN    30-Jul-07   \n",
       "262                      NaN              NaN    11-Jul-07   \n",
       "263                      NaN              NaN    12-Jun-07   \n",
       "264                      NaN              NaN     1-Jun-07   \n",
       "265                      NaN              NaN     6-Apr-07   \n",
       "266                      NaN              NaN     2-Apr-07   \n",
       "267                      NaN              NaN    22-Feb-07   \n",
       "268                      NaN              NaN    15-Sep-06   \n",
       "269                   Dec-09           Dec-09    20-Jun-06   \n",
       "270                   Mar-15           Mar-15    20-Jun-06   \n",
       "271                      NaN              NaN    17-Feb-06   \n",
       "272                      NaN              NaN    15-Feb-06   \n",
       "273                      NaN              NaN    28-Oct-05   \n",
       "274                      NaN              NaN    27-Oct-05   \n",
       "275                   Nov-11           Nov-11    16-Aug-05   \n",
       "276                   Aug-05              NaN     1-Dec-04   \n",
       "277                   Oct-11           Oct-11    11-Oct-04   \n",
       "278                   Feb-07           Feb-07    25-Dec-03   \n",
       "279                   Apr-14           Apr-14    12-Jun-03   \n",
       "280                      NaN              NaN     1-Aug-02   \n",
       "281                      NaN              NaN     4-Jul-02   \n",
       "\n",
       "    Results First Posted  Last Update Posted  \\\n",
       "0                    NaN           25-Jun-18   \n",
       "1                    NaN           19-Jun-18   \n",
       "2                    NaN           18-Jun-18   \n",
       "3                    NaN           18-Jun-18   \n",
       "4                    NaN           18-Jun-18   \n",
       "5                    NaN            1-Jun-18   \n",
       "6                    NaN           28-May-18   \n",
       "7                    NaN           28-May-18   \n",
       "8                    NaN            7-Jun-18   \n",
       "9                    NaN           23-May-18   \n",
       "10                   NaN           22-May-18   \n",
       "11                   NaN           12-Jun-18   \n",
       "12                   NaN            4-Jun-18   \n",
       "13                   NaN           18-Apr-18   \n",
       "14                   NaN           10-Apr-18   \n",
       "15                   NaN           10-Apr-18   \n",
       "16                   NaN           25-Apr-18   \n",
       "17                   NaN           13-Mar-18   \n",
       "18                   NaN           22-Feb-18   \n",
       "19                   NaN           15-Feb-18   \n",
       "20                   NaN            9-May-18   \n",
       "21                   NaN            2-Feb-18   \n",
       "22                   NaN            6-Feb-18   \n",
       "23                   NaN           30-Jan-18   \n",
       "24                   NaN           26-Jan-18   \n",
       "25                   NaN            8-May-18   \n",
       "26                   NaN           12-Jun-18   \n",
       "27                   NaN           10-Jan-18   \n",
       "28                   NaN           10-Jan-18   \n",
       "29                   NaN            4-Jan-18   \n",
       "..                   ...                 ...   \n",
       "252                  NaN           14-Apr-08   \n",
       "253                  NaN            1-Apr-08   \n",
       "254                  NaN           27-Sep-16   \n",
       "255                  NaN           29-Jan-15   \n",
       "256                  NaN           21-Jul-16   \n",
       "257                  NaN           13-May-16   \n",
       "258                  NaN           23-Jul-12   \n",
       "259                  NaN           27-Nov-13   \n",
       "260                  NaN            6-Feb-14   \n",
       "261                  NaN           15-Dec-14   \n",
       "262                  NaN            2-Aug-11   \n",
       "263                  NaN           15-Apr-08   \n",
       "264                  NaN           17-Jan-14   \n",
       "265                  NaN           30-Mar-11   \n",
       "266                  NaN           12-May-10   \n",
       "267                  NaN            6-May-14   \n",
       "268                  NaN           22-Apr-16   \n",
       "269                  NaN            4-Apr-13   \n",
       "270                  NaN            6-Apr-16   \n",
       "271                  NaN            9-Feb-12   \n",
       "272                  NaN           11-Feb-14   \n",
       "273                  NaN           11-Apr-14   \n",
       "274                  NaN           13-Apr-18   \n",
       "275                  NaN            9-Mar-12   \n",
       "276                  NaN           30-Nov-16   \n",
       "277                  NaN            9-Mar-12   \n",
       "278                  NaN            5-Feb-14   \n",
       "279                  NaN           30-Nov-16   \n",
       "280                  NaN            7-Jan-14   \n",
       "281                  NaN           15-Mar-07   \n",
       "\n",
       "                                             Locations Study Documents  \\\n",
       "0                                                  NaN             NaN   \n",
       "1                                                  NaN             NaN   \n",
       "2                                                  NaN             NaN   \n",
       "3                                                  NaN             NaN   \n",
       "4                                                  NaN             NaN   \n",
       "5                                                  NaN             NaN   \n",
       "6                                                  NaN             NaN   \n",
       "7                                                  NaN             NaN   \n",
       "8                                                  NaN             NaN   \n",
       "9    Hospital Sirio Libanes, Sao Paulo, São Paulo, ...             NaN   \n",
       "10                                                 NaN             NaN   \n",
       "11                                                 NaN             NaN   \n",
       "12   Stanford Cancer Institute Palo Alto, Palo Alto...             NaN   \n",
       "13                                                 NaN             NaN   \n",
       "14                                                 NaN             NaN   \n",
       "15                                                 NaN             NaN   \n",
       "16                                                 NaN             NaN   \n",
       "17   GSK Investigational Site, San Francisco, Calif...             NaN   \n",
       "18                                                 NaN             NaN   \n",
       "19                                                 NaN             NaN   \n",
       "20   Sleep Disorders Center of Alabama, Birmingham,...             NaN   \n",
       "21   Florida Hospital Cancer Institute, Orlando, Fl...             NaN   \n",
       "22                           Salma Komy, Assiut, Egypt             NaN   \n",
       "23                                                 NaN             NaN   \n",
       "24   Neurosurgery, Tel-Aviv Sourasky MC, Tel Aviv, ...             NaN   \n",
       "25                                                 NaN             NaN   \n",
       "26   Mayo Clinic Cancer Center, Scottsdale, Arizona...             NaN   \n",
       "27                                                 NaN             NaN   \n",
       "28                                                 NaN             NaN   \n",
       "29                                                 NaN             NaN   \n",
       "..                                                 ...             ...   \n",
       "252                                                NaN             NaN   \n",
       "253                                                NaN             NaN   \n",
       "254                                                NaN             NaN   \n",
       "255                                                NaN             NaN   \n",
       "256                                                NaN             NaN   \n",
       "257  Vanderbilt University, Nashville, Tennessee, U...             NaN   \n",
       "258  University of Nebraska Medical Center, Omaha, ...             NaN   \n",
       "259                                                NaN             NaN   \n",
       "260  Sheffield, Alabama, United States|Anchorage, A...             NaN   \n",
       "261  University of CA at San Francisco Hospitals an...             NaN   \n",
       "262  Birmingham, Alabama, United States|Anchorage, ...             NaN   \n",
       "263  Los Angeles, California, United States|Orange,...             NaN   \n",
       "264                                                NaN             NaN   \n",
       "265                                                NaN             NaN   \n",
       "266  Local Institution, Busan, Korea, Republic of|L...             NaN   \n",
       "267  Anthony Botti, Livingston, New Jersey, United ...             NaN   \n",
       "268                                                NaN             NaN   \n",
       "269                                                NaN             NaN   \n",
       "270  Novartis Investigative Site, Huntsville, Alaba...             NaN   \n",
       "271  The Children's Hospital of Philadelphia, Phila...             NaN   \n",
       "272                                                NaN             NaN   \n",
       "273  Anniston, Alabama, United States|Birmingham, A...             NaN   \n",
       "274  GSK Investigational Site, Birmingham, Alabama,...             NaN   \n",
       "275  Pfizer Investigational Site, Scottsdale, Arizo...             NaN   \n",
       "276  1182.70.127 Health Services Center, Inc., Anni...             NaN   \n",
       "277  Pfizer Investigational Site, Duarte, Californi...             NaN   \n",
       "278                                                NaN             NaN   \n",
       "279  1182.58.31, Scottsdale, Arizona, United States...             NaN   \n",
       "280                                                NaN             NaN   \n",
       "281  For additional information regarding investiga...             NaN   \n",
       "\n",
       "                                             URL  \n",
       "0    https://ClinicalTrials.gov/show/NCT03564964  \n",
       "1    https://ClinicalTrials.gov/show/NCT03561194  \n",
       "2    https://ClinicalTrials.gov/show/NCT03559686  \n",
       "3    https://ClinicalTrials.gov/show/NCT03559673  \n",
       "4    https://ClinicalTrials.gov/show/NCT03559660  \n",
       "5    https://ClinicalTrials.gov/show/NCT03544060  \n",
       "6    https://ClinicalTrials.gov/show/NCT03539393  \n",
       "7    https://ClinicalTrials.gov/show/NCT03539380  \n",
       "8    https://ClinicalTrials.gov/show/NCT03537807  \n",
       "9    https://ClinicalTrials.gov/show/NCT03533361  \n",
       "10   https://ClinicalTrials.gov/show/NCT03532516  \n",
       "11   https://ClinicalTrials.gov/show/NCT03503890  \n",
       "12   https://ClinicalTrials.gov/show/NCT03501940  \n",
       "13   https://ClinicalTrials.gov/show/NCT03501615  \n",
       "14   https://ClinicalTrials.gov/show/NCT03493165  \n",
       "15   https://ClinicalTrials.gov/show/NCT03493152  \n",
       "16   https://ClinicalTrials.gov/show/NCT03492489  \n",
       "17   https://ClinicalTrials.gov/show/NCT03462810  \n",
       "18   https://ClinicalTrials.gov/show/NCT03439475  \n",
       "19   https://ClinicalTrials.gov/show/NCT03433807  \n",
       "20   https://ClinicalTrials.gov/show/NCT03433131  \n",
       "21   https://ClinicalTrials.gov/show/NCT03420430  \n",
       "22   https://ClinicalTrials.gov/show/NCT03419949  \n",
       "23   https://ClinicalTrials.gov/show/NCT03414489  \n",
       "24   https://ClinicalTrials.gov/show/NCT03412539  \n",
       "25   https://ClinicalTrials.gov/show/NCT03409081  \n",
       "26   https://ClinicalTrials.gov/show/NCT03400098  \n",
       "27   https://ClinicalTrials.gov/show/NCT03395769  \n",
       "28   https://ClinicalTrials.gov/show/NCT03395743  \n",
       "29   https://ClinicalTrials.gov/show/NCT03386071  \n",
       "..                                           ...  \n",
       "252  https://ClinicalTrials.gov/show/NCT00650026  \n",
       "253  https://ClinicalTrials.gov/show/NCT00649545  \n",
       "254  https://ClinicalTrials.gov/show/NCT00642057  \n",
       "255  https://ClinicalTrials.gov/show/NCT00590382  \n",
       "256  https://ClinicalTrials.gov/show/NCT00584064  \n",
       "257  https://ClinicalTrials.gov/show/NCT00580658  \n",
       "258  https://ClinicalTrials.gov/show/NCT00575549  \n",
       "259  https://ClinicalTrials.gov/show/NCT00528320  \n",
       "260  https://ClinicalTrials.gov/show/NCT00520143  \n",
       "261  https://ClinicalTrials.gov/show/NCT00508963  \n",
       "262  https://ClinicalTrials.gov/show/NCT00499720  \n",
       "263  https://ClinicalTrials.gov/show/NCT00484991  \n",
       "264  https://ClinicalTrials.gov/show/NCT00481559  \n",
       "265  https://ClinicalTrials.gov/show/NCT00457548  \n",
       "266  https://ClinicalTrials.gov/show/NCT00454753  \n",
       "267  https://ClinicalTrials.gov/show/NCT00438789  \n",
       "268  https://ClinicalTrials.gov/show/NCT00377065  \n",
       "269  https://ClinicalTrials.gov/show/NCT00338442  \n",
       "270  https://ClinicalTrials.gov/show/NCT00338247  \n",
       "271  https://ClinicalTrials.gov/show/NCT00293098  \n",
       "272  https://ClinicalTrials.gov/show/NCT00291811  \n",
       "273  https://ClinicalTrials.gov/show/NCT00245739  \n",
       "274  https://ClinicalTrials.gov/show/NCT00244686  \n",
       "275  https://ClinicalTrials.gov/show/NCT00130897  \n",
       "276  https://ClinicalTrials.gov/show/NCT00097799  \n",
       "277  https://ClinicalTrials.gov/show/NCT00094029  \n",
       "278  https://ClinicalTrials.gov/show/NCT00074919  \n",
       "279  https://ClinicalTrials.gov/show/NCT00062660  \n",
       "280  https://ClinicalTrials.gov/show/NCT00042393  \n",
       "281  https://ClinicalTrials.gov/show/NCT00040625  \n",
       "\n",
       "[282 rows x 27 columns]"
      ]
     },
     "execution_count": 38,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.head(1000)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "180\n"
     ]
    }
   ],
   "source": [
    "interventions = df['Interventions'].dropna()\n",
    "drugs=[]\n",
    "\n",
    "for intervention in interventions:\n",
    "    if((intervention[0:5] == \"Drug:\") and (intervention not in drugs)):\n",
    "        drugs.append(intervention)\n",
    "print(len(drugs))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Drug: SUVN-502\n",
      "Drug: Certolizumab Pegol\n",
      "Drug: Lacosamide\n",
      "Drug: Volanesorsen\n",
      "Drug: Fremanezumab\n",
      "Drug: TRx0237\n",
      "Drug: Riluzole\n",
      "Drug: Lenvatinib\n",
      "Drug: Brivaracetam\n",
      "Drug: rovalpituzumab tesirine\n",
      "Drug: Moxetumomab Pasudotox\n",
      "Drug: Everolimus\n",
      "Drug: cemiplimab\n",
      "Drug: cabotegravir, CAB\n",
      "Drug: Idebenone\n",
      "Drug: Pitolisant\n",
      "Drug: oral lamotrigine 100 mg|Drug: oral pregabalin 150 mg\n",
      "Drug: ABC294640\n",
      "Drug: gilteritinib\n",
      "Drug: Inotersen\n",
      "Drug: Trametinib 2 mg\n",
      "Drug: Fostamatinib disodium 100 mg|Drug: Fostamatinib disodium 150 mg\n",
      "Drug: Ustekinumab\n",
      "Drug: ARQ 092\n",
      "Drug: tezacaftor/ivacaftor\n",
      "Drug: Selumetinib\n",
      "Drug: LJPC-501\n",
      "Drug: ivosidenib (AG-120)\n",
      "Drug: LOXO-195\n",
      "Drug: Cannabidiol oral solution\n",
      "Drug: Lorlatinib\n",
      "Drug: Glassia\n",
      "Drug: Ruxolitinib\n",
      "Drug: VAL-083\n",
      "Drug: Inotuzumab Ozogamicin\n",
      "Drug: glecaprevir|Drug: pibrentasvir\n",
      "Drug: ABT-414\n",
      "Drug: Veliparib\n",
      "Drug: Venetoclax\n",
      "Drug: Avelumab\n",
      "Drug: Olaparib tablets\n",
      "Drug: Omegaven\n",
      "Drug: 3,4-Diaminopyridine\n",
      "Drug: Ganitumab\n",
      "Drug: Niraparib\n",
      "Drug: larotrectinib\n",
      "Drug: Dupilumab\n",
      "Drug: 131-I-meta-iodobenzylguanidine\n",
      "Drug: Veliparib|Drug: Cisplatin|Drug: Vinorelbine\n",
      "Drug: BMN190, recombinant human tripeptidyl peptidase-1 (rhTPP1)\n",
      "Drug: Ultratrace Iobenguane I131\n",
      "Drug: patisiran (ALN-TTR02)\n",
      "Drug: HBOC-201\n",
      "Drug: Omegaven IV lipid emulsion\n",
      "Drug: 4-Demethyl-4-cholesteryloxycarbonylpenclomedine\n",
      "Drug: nusinersen\n",
      "Drug: Elotuzumab|Drug: Lenalidomide|Drug: Dexamethasone\n",
      "Drug: Pasireotide\n",
      "Drug: Carbon-11 Sodium Acetate\n",
      "Drug: Abemaciclib\n",
      "Drug: Pimavanserin tartrate\n",
      "Drug: MT-3724\n",
      "Drug: 177Lu-DOTA0-Tyr3-Octreotate\n",
      "Drug: Estradiol 2Mg Tablet\n",
      "Drug: Cannabidiol\n",
      "Drug: Deferiprone\n",
      "Drug: LY2503029\n",
      "Drug: Midostaurin\n",
      "Drug: Brincidofovir\n",
      "Drug: Deflazacort\n",
      "Drug: Atezolizumab [TECENTRIQ]\n",
      "Drug: Panobinostat\n",
      "Drug: Domperidone\n",
      "Drug: 18 F-DOPA\n",
      "Drug: CPX-351\n",
      "Drug: 11C-choline|Device: PET/CT Scan\n",
      "Drug: Oral Domperidone\n",
      "Drug: Daratumumab\n",
      "Drug: Crizotinib\n",
      "Drug: PCI-32765 (Ibrutinib)\n",
      "Drug: [18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA)\n",
      "Drug: SMOFlipid\n",
      "Drug: Tacrolimus\n",
      "Drug: Cannabidiol (Epidiolex)\n",
      "Drug: LCZ696\n",
      "Drug: Elotuzumab in combination with Lenalidomide and Dexamethasone\n",
      "Drug: C-11 Choline PET Imaging\n",
      "Drug: Perampanel\n",
      "Drug: TAS-102\n",
      "Drug: Stiripentol\n",
      "Drug: Phase I Dose-finding Study of Sorafenib Study\n",
      "Drug: suspension of erythrocytes encapsulating L-asparaginase\n",
      "Drug: Amifampridine Phosphate\n",
      "Drug: Blinatumomab\n",
      "Drug: 68Ga DOTATATE\n",
      "Drug: nintedanib\n",
      "Drug: Pirfenidone\n",
      "Drug: Idelalisib|Drug: Rituximab\n",
      "Drug: Tecovirimat\n",
      "Drug: Fenretinide Lym-X-Sorb Oral Powder|Drug: Ketoconazole\n",
      "Drug: Abroma Augusta Q (mother tincture)\n",
      "Drug: Triheptanoin\n",
      "Drug: 3,4-diaminopyridine\n",
      "Drug: Pasireotide long acting release formulation\n",
      "Drug: LDK378\n",
      "Drug: Afatinib\n",
      "Drug: Triclabendazole\n",
      "Drug: Adding Magnesium Sulfate to the standard epidural and interscalene blocks for chronic pain\n",
      "Drug: Fleet enema\n",
      "Drug: 18F-DOPA\n",
      "Drug: sildenafil\n",
      "Drug: gemtuzumab ozogamicin|Other: laboratory biomarker analysis\n",
      "Drug: Omegaven 10%\n",
      "Drug: BMN 110\n",
      "Drug: 3, 4-Diaminopyridine\n",
      "Drug: Dextromethorphan\n",
      "Drug: Sofosbuvir|Drug: Ribavirin|Drug: Pegylated Interferon\n",
      "Drug: Baricitinib\n",
      "Drug: cabozantinib\n",
      "Drug: Arbekacin Sulfate\n",
      "Drug: afatinib\n",
      "Drug: Paromomycin\n",
      "Drug: Pomalidomide\n",
      "Drug: MDV3100\n",
      "Drug: ponatinib\n",
      "Drug: Diclofenac\n",
      "Drug: Macugen (Pegaptanib Sodium)\n",
      "Drug: migalastat HCl\n",
      "Drug: TMC207\n",
      "Drug: triheptanoin\n",
      "Drug: uridine triacetate\n",
      "Drug: Carfilzomib\n",
      "Drug: VX-770\n",
      "Drug: 131 I-Metaiodobenzylguanidine (131 I-MIBG)\n",
      "Drug: Metaiodobenzylguanidine (MIBG)\n",
      "Drug: Bortezomib/Dexamethasone/Melphalan\n",
      "Drug: Eribulin Mesylate\n",
      "Drug: Voclosporin\n",
      "Drug: Abiraterone Acetate|Drug: Prednisone\\Prednisolone\n",
      "Drug: docetaxel oxaliplatin\n",
      "Drug: Paclitaxel Cisplatin\n",
      "Drug: BIBW 2992\n",
      "Drug: CTH Chronic Hepatitis B\n",
      "Drug: brentuximab vedotin\n",
      "Drug: 131 I-Metaiodobenzylguanidine (131 I-MIBG)|Drug: 131 I-MIBG\n",
      "Drug: vismodegib (GDC-0449)\n",
      "Drug: SCB01A\n",
      "Drug: 3,4 diaminopyridine\n",
      "Drug: Aztreonam lysine\n",
      "Drug: Rosuvastatin,SFC fenofibrate\n",
      "Drug: velaglucerase alfa\n",
      "Drug: rosuvastatin,fenofibrate|Genetic: CYP2C9, UGT1A1, UGT1A3, OATP2, BCRP\n",
      "Drug: Tipranavir\n",
      "Drug: Oxcarbazepine Extended Release\n",
      "Drug: Nilotinib\n",
      "Drug: droxidopa\n",
      "Drug: Dasatinib and Imatinib\n",
      "Drug: OFF in experimental arm\n",
      "Drug: Miralax\n",
      "Drug: Iobenguane I 123 Injection\n",
      "Drug: Belatacept\n",
      "Drug: 3, 4 DAP\n",
      "Drug: tetrabenazine\n",
      "Drug: sodium stibogluconate (Pentostam)\n",
      "Drug: Aztreonam Lysine for Inhalation\n",
      "Drug: Sapropterin dihydrochloride\n",
      "Drug: Voraxaze (glucarpidase)\n",
      "Drug: Dasatinib\n",
      "Drug: eculizumab\n",
      "Drug: raltegravir\n",
      "Drug: VariZIG™\n",
      "Drug: lapatinib + capecitabine\n",
      "Drug: deferiprone\n",
      "Drug: AMD3100 + G-CSF\n",
      "Drug: TMC-114\n",
      "Drug: Mepolizumab\n",
      "Drug: Sutent\n",
      "Drug: Tipranavir|Drug: Ritonavir\n",
      "Drug: Adefovir Dipivoxil\n",
      "Drug: Pemetrexed|Drug: Cisplatin\n"
     ]
    }
   ],
   "source": [
    "for drug in drugs:\n",
    "    print(drug)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "with open(\"expanded_acess_avilable+marketing.txt\", 'w') as file_handler:\n",
    "    for drug in drugs:\n",
    "        file_handler.write(\"{}\\n\".format(drug))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.6.2"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
